Search results
The LumiraDx SARS-CoV-2 Ag Test is a microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal swab specimens. For patients suspected of COVID-19 or asymptomatic indviduals, lab-comparable results in minutes
The LumiraDx SAR-CoV-2 Ag Test is a single use fluorescence immunoassay device designed to detect the presence of the nucleocapsid protein antigen directly from SARS-CoV-2 in either...
Use of code 87635 will help to efficiently report and track testing services related to SARS-CoV-2 and will streamline the reporting and reim-bursement for this test in the United States.
- 260KB
- 4
The LumiraDx SARS-CoV-2 Ag Test is a rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform. Intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from nasal swab and nasopharyngeal swab samples collected from individuals
The LumiraDx SAR-CoV-2 Ag Test is a single use fluorescence immunoassay device designed to detect the presence of the nucleocapsid protein antigen directly from SARS-CoV-2 in either anterior nasal swab or nasopharyngeal swab samples, without transport media.
• The LumiraDx SARS-CoV-2 Ag Test can be used to test direct anterior nasal swab and nasopharyngeal swab specimens. • The LumiraDx SARS-CoV-2 Ag Test should be ordered for the...
The LumiraDx SARS-CoV-2 Ag Test is only authorized for use in laboratories in the United States, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate, high and waived complexity tests. This test is authorized for use at the point of care (POC), i.e., in patient care
